Overview
LTRN market data
Price History
LTRN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.57 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.29 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.11 – $4.86 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $34.2M · P/B 5.19.
Company News
Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) EstimateBenzinga · Aug 14, 2026, 11:43 AM
8-K filing — Lantern Pharma Inc. (LTRN)SEC EDGAR · Aug 14, 2026, 11:35 AM
Lantern Pharma Creates Open-Medicine AI As Separate EntityBenzinga · Aug 3, 2026, 11:34 AM
Lantern Pharma Announces EMA Clearance Of An Investigator-Initiated Phase 1b/2 Clinical Trial Of LP-184 In Advanced, Recurrent Bladder CancerBenzinga · Jul 28, 2026, 11:47 AM
Lantern Pharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For 'Methods For The Treatment Of Solid Tumor Cancers Using Illudins And Biomarkers'Benzinga · Jul 23, 2026, 12:09 PM
Lantern Pharma Launches ZetaOmics, A Computational-Biology Module Of Its WithZeta.ai Co-Scientist PlatformBenzinga · Jul 8, 2026, 11:40 AM
Lantern Pharma Announces Selling Stockholders May Sell Up To 2.24M Shares Of Common StockBenzinga · Jun 12, 2026, 8:40 PM
Lantern Pharma Reports Clinical Data And Updates From Ongoing Phase 2 HARMONIC Trial Evaluating LP-300 In Combination With Carboplatin And Pemetrexed In Patients With EGFR Exon 21 L858R-Mutant NSCLCBenzinga · Jun 2, 2026, 12:19 PM
Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer AdenocarcinomaBenzinga · May 19, 2026, 11:40 AM
Lantern Pharma shares are trading lower. The company reported Q1 financial results.Benzinga · May 15, 2026, 9:03 PM